Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Savonenko AV, Melnikova T, Hiatt A, Li T, Worley PF, Troncoso JC, Wong PC, Price DL.

Neuropsychopharmacology. 2012 Jan;37(1):261-77. doi: 10.1038/npp.2011.211. Epub 2011 Sep 21. Review.

2.

Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.

Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CF.

Drugs R D. 2006;7(2):87-97. Review.

PMID:
16542055
3.

Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?

Banik A, Brown RE, Bamburg J, Lahiri DK, Khurana D, Friedland RP, Chen W, Ding Y, Mudher A, Padjen AL, Mukaetova-Ladinska E, Ihara M, Srivastava S, Padma Srivastava MV, Masters CL, Kalaria RN, Anand A.

J Alzheimers Dis. 2015;47(4):815-43. doi: 10.3233/JAD-150136. Review.

PMID:
26401762
4.

The evolution of preclinical Alzheimer's disease: implications for prevention trials.

Sperling R, Mormino E, Johnson K.

Neuron. 2014 Nov 5;84(3):608-22. doi: 10.1016/j.neuron.2014.10.038. Epub 2014 Nov 5. Review.

5.

Discovery of notch-sparing gamma-secretase inhibitors.

Augelli-Szafran CE, Wei HX, Lu D, Zhang J, Gu Y, Yang T, Osenkowski P, Ye W, Wolfe MS.

Curr Alzheimer Res. 2010 May;7(3):207-9. Review.

6.

Preclinical Alzheimer's disease therapeutics.

Rafii MS.

J Alzheimers Dis. 2014;42 Suppl 4:S545-9. doi: 10.3233/JAD-141482. Review.

PMID:
25079804
7.
8.

gamma-Secretase as a target for drug intervention in Alzheimer's disease.

Harrison T, Churcher I, Beher D.

Curr Opin Drug Discov Devel. 2004 Sep;7(5):709-19. Review.

PMID:
15503873
9.

Animal models of Alzheimer's disease and drug development.

Laurijssens B, Aujard F, Rahman A.

Drug Discov Today Technol. 2013 Sep;10(3):e319-27. doi: 10.1016/j.ddtec.2012.04.001. Review.

PMID:
24050129
10.

Novel approaches to models of Alzheimer's disease pathology for drug screening and development.

Shaughnessy L, Chamblin B, McMahon L, Nair A, Thomas MB, Wakefield J, Koentgen F, Ramabhadran R.

J Mol Neurosci. 2004;24(1):23-32. Review.

PMID:
15314246
11.

[Pharmacology of Alzheimer's disease: where do we go from here?].

Sellal F, Nieoullon A, Michel G, Michel BF, Lacomblez L, Geerts H, Delini-Stula A, Bentué-Ferrer D, Bordet R, Allain H.

Therapie. 2005 Mar-Apr;60(2):89-107. Review. French.

PMID:
15969312
12.

Resolving controversies on the path to Alzheimer's therapeutics.

Selkoe DJ.

Nat Med. 2011 Sep 7;17(9):1060-5. doi: 10.1038/nm.2460. Erratum in: Nat Med. 2011 Nov;17(11):1521. Nat Med. 2011 Dec;17(12):1693.

PMID:
21900936
13.

Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.

Golde TE, Schneider LS, Koo EH.

Neuron. 2011 Jan 27;69(2):203-13. doi: 10.1016/j.neuron.2011.01.002.

14.

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Curr Med Chem. 2011;18(35):5430-47. Review.

PMID:
22087836
15.

Alzheimer's disease drug development: translational neuroscience strategies.

Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K.

CNS Spectr. 2013 Jun;18(3):128-38. doi: 10.1017/S1092852913000023. Epub 2013 Mar 11. Review.

PMID:
23472637
16.

Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease.

Schneider LS.

Alzheimers Dement. 2014 Mar;10(2):247-50. doi: 10.1016/j.jalz.2013.12.002.

17.

NIA commentary: translational issues in Alzheimer's disease drug development.

Buckholtz NS, Ryan LM, Petanceska S, Refolo LM.

Neuropsychopharmacology. 2012 Jan;37(1):284-6. doi: 10.1038/npp.2011.116. No abstract available.

18.

In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease.

Semighini EP.

Chem Biol Drug Des. 2015 Sep;86(3):284-90. doi: 10.1111/cbdd.12492. Epub 2014 Dec 28.

PMID:
25476252
19.

Neuroimaging outcomes in clinical trials in Alzheimer's disease.

Frisoni GB, Delacourte A.

J Nutr Health Aging. 2009 Mar;13(3):209-12. Review.

PMID:
19262955
20.

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.

D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A.

Expert Opin Drug Discov. 2012 Jan;7(1):19-37. doi: 10.1517/17460441.2012.645534. Epub 2011 Dec 14. Review.

PMID:
22468891

Supplemental Content

Support Center